Fujirebio Europe N.V.

https://www.fujirebio-europe.com

Innogenetics is an international biopharmaceutical company building parallel businesses in the areas of specialty diagnostics and therapeutic vaccines.

In 2006, total revenues (product sales, royalties, and license fees) reached €53.7 million. Its Diagnostics Division develops a large number of specialty products covering five areas: infectious diseases (hepatitis C, hepatitis B, HIV, and HPV), genetic testing (cystic fibrosis), tissue typing (HLA), neurodegeneration (Alzheimer's disease), and cancer. In its Therapeutics Division, Innogenetics focuses on the development of therapeutic vaccines to address unmet medical needs in the field of infectious diseases.

Founded in 1985, Innogenetics is listed on Euronext Brussels [Ticker: INNX]. Innogenetics' headquarters are in Gent, Belgium, with sales subsidiaries in France, Germany, Italy, Spain, Brazil, and the United States and an associate in the United Kingdom. Innogenetics employs 495 people worldwide and has a market capitalization of approximately €255 million. *

	Start	2013-10-01 renamed
	Group	Miraca (Group)
	Predecessor	Innogenetics N.V.
	Industry	BIOTECH
	Industry 2	diagnostics (medical/biological)

	Region	Gent (Ghent)
	Country	Belgium
	Street	6 Technologiepark
	City	9052 Gent
	Tel	+32-9-329-1329
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2009-01-01)
	Currency	EUR
	Annual sales	54,100,000 (revenues, consolidated (2007) 2007-12-31)
	Profit	-17,400,000 (2007-12-31)
	Cash	23,400,000 (2007-12-31)

		* Document for »About Section«:

		Record changed: 2024-02-12

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Miraca (Group)

[1] Qiagen N.V.. (8/1/18). "Press Release: Qiagen Creates Collaboration with Japan’s Largest Clinical Laboratory Testing Company, SRL, to Accelerate Faunch of Companion Diagnostics". Hilden & Tokyo....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]